# Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

> **NCT03137992** · PHASE3 · COMPLETED · sponsor: **Lupin, Inc.** · enrollment: 377 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** Test Product (tiotropium bromide inhalation powder)
- **DRUG:** Reference Product (Spiriva®)

## Key facts

- **NCT ID:** NCT03137992
- **Lead sponsor:** Lupin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-21
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-04-30
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137992, "Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03137992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*